Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Xinchun Jin, Jie Liu and Wenlan Liu
Pages 254-262 (9)
Tissue plasminogen activator (tPA) thrombolysis, remains to be the only United States Food and Drug
Administration (FDA) approved treatment for acute ischemia stroke. However, the use of tPA has been profoundly
constrained due to its narrow therapeutic time window and the increased risk of potentially deadly hemorrhagic
complications. TPA-associated hemorrhagic transformation (HT) often occurs as a result of catastrophic failure of the
blood brain barrier (BBB), wherein the affected cerebral capillaries can no longer hold blood constituents. Due to its
direct contribution to edema and HT, reperfusion-associated BBB damage has been extensively studied, while BBB
damage that occurs within the thrombolytic time window is largely neglected. Of note, ischemia-induced BBB damage in
the early stroke stages is increasingly appreciated to negatively affect the safety and efficacy profiles of thrombolytic
therapy for ischemic stroke. In this review, we discussed the recent findings of spatio-temporal evolution of BBB injury in
the early stages of cerebral ischemia and its association with intracerebral hemorrhage following tPA thrombolysis. The
increased understanding of early ischemic BBB damage and its close link to tPA-associated HT is of particular
importance for developing new preventive and therapeutic strategies to reduce the hemorrhagic complications in stroke
Blood brain barrier, hemorrhage transformation, ischemia stroke, matrix metalloproteinase, thrombolysis, tight
junction proteins, tissue plasminogen activator.
The Central Laboratory of Shenzhen Second People's Hospital, Shenzhen University First Affiliated Hospital Shenzhen, China, 518035.